» Articles » PMID: 9114023

Mutations in Mitochondrial Cytochrome C Oxidase Genes Segregate with Late-onset Alzheimer Disease

Overview
Specialty Science
Date 1997 Apr 29
PMID 9114023
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Mounting evidence suggests that defects in energy metabolism contribute to the pathogenesis of Alzheimer disease (AD). Cytochrome c oxidase (CO) is kinetically abnormal, and its activity is decreased in brain and peripheral tissue in late-onset AD. CO is encoded by both the mitochondrial and the nuclear genomes. Its catalytic centers, however, are encoded exclusively by two mitochondrial genes, CO1 and CO2 (encoding CO subunits I and II, respectively). We searched these genes, as well as other mitochondrial genes, for mutations that might alter CO activity and cosegregate with AD. In the present study, specific missense mutations in the mitochondrial CO1 and CO2 genes but not the CO3 gene were found to segregate at a higher frequency with AD compared with other neurodegenerative or metabolic diseases. These mutations appear together in the same mitochondrial DNA molecule and define a unique mutant mitochondrial genome. Asymptomatic offspring of AD mothers had higher levels of these mutations than offspring of AD fathers, suggesting that these mutations can be maternally inherited. Cell lines expressing these mutant mitochondrial DNA molecules exhibited a specific decrease in CO activity and increased production of reactive oxygen species. We suggest that specific point mutations in the CO1 and CO2 genes cause the CO defect in AD. A CO defect may represent a primary etiologic event, directly participating in a cascade of events that results in AD.

Citing Articles

Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives.

Bhole R, Chikhale R, Rathi K IBRO Neurosci Rep. 2024; 16:8-42.

PMID: 38169888 PMC: 10758887. DOI: 10.1016/j.ibneur.2023.11.003.


The Mighty NUMT: Mitochondrial DNA Flexing Its Code in the Nuclear Genome.

Xue L, Moreira J, Smith K, Fetterman J Biomolecules. 2023; 13(5).

PMID: 37238623 PMC: 10216076. DOI: 10.3390/biom13050753.


Selected Biomarkers of Oxidative Stress and Energy Metabolism Disorders in Neurological Diseases.

Korczowska-Lacka I, Hurla M, Banaszek N, Kobylarek D, Szymanowicz O, Kozubski W Mol Neurobiol. 2023; 60(7):4132-4149.

PMID: 37039942 PMC: 10224870. DOI: 10.1007/s12035-023-03329-4.


Is Mitochondria DNA Variation a Biomarker for AD?.

Gao R, Ma S Genes (Basel). 2022; 13(10).

PMID: 36292674 PMC: 9601433. DOI: 10.3390/genes13101789.


Use of Next-Generation Sequencing for Identifying Mitochondrial Disorders.

Mahmud S, Biswas S, Afrose S, Mita M, Hasan M, Shimu M Curr Issues Mol Biol. 2022; 44(3):1127-1148.

PMID: 35723297 PMC: 8947152. DOI: 10.3390/cimb44030074.


References
1.
Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

2.
Swerdlow R, Parks J, Miller S, Tuttle J, Trimmer P, Sheehan J . Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol. 1996; 40(4):663-71. DOI: 10.1002/ana.410400417. View

3.
Hansen L, Salmon D, Galasko D, Masliah E, Katzman R, DeTeresa R . The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990; 40(1):1-8. DOI: 10.1212/wnl.40.1.1. View

4.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N . Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996; 2(8):864-70. DOI: 10.1038/nm0896-864. View

5.
Parker Jr W, Mahr N, Filley C, Parks J, Hughes D, Young D . Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology. 1994; 44(6):1086-90. DOI: 10.1212/wnl.44.6.1086. View